Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management

被引：235

作者：

Wang, Yongzhi ^{[1
]}

Jiang, Tao ^{[1
]}

机构：

[1] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China

来源：

CANCER LETTERS | 2013年 / 331卷 / 02期

关键词：

Molecular targeted therapy; Brain tumor; Surgery; Prognosis; PHASE-II TRIAL; ANAPLASTIC OLIGODENDROGLIAL TUMORS; NEWLY-DIAGNOSED GLIOBLASTOMA; BEVACIZUMAB PLUS IRINOTECAN; PROGRESSION-FREE SURVIVAL; QUALITY-OF-LIFE; RECURRENT GLIOBLASTOMA; IDH2; MUTATIONS; EUROPEAN ORGANIZATION; RADIATION-THERAPY;

D O I：

10.1016/j.canlet.2012.12.024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-grade gliomas (HGGs) account for the vast majority of all gliomas, including glioblastoma (World Health Organization (WHO) grade IV) and anaplasticgliomas (WHO grade III). Despite tremendous efforts in developing multimodal treatments, the overall prognosis remains poor; however, survival time varies considerably between patients. The nature of diffuse permeation into surrounding brain parenchyma poses dilemma for neurosurgeons between extensive surgical resection to eliminate as much as tumor cells as possible and adverse effects associated with brain function. Heterogeneity in both cytology and gene expression makes it difficult to coordinate an effective therapy which works for every patient. This article reviews recent advancements in the molecular mechanism, multimodal treatment and clinical management, and the updated view on the biomarkers in patients with HGG, both in primary and recurrent setting, with an emphasis on targeted therapies tailored to the patient. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：139 / 146

页数：8

共 117 条

[41]

Iyer G., 2012, SCIENCE

[42] Irinotecan and bevacizumab in recurrent glioblastoma multiforme [J].

Jakobsen, Jan Nyrop ;

Hasselbalch, Benedikte ;

Stockhausen, Marie-Therese ;

Lassen, Ulrik ;

Poulsen, Hans Skovgaard .

EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (05) :825-833

[43] Molecular pathogenesis of oligodendroglial tumors [J].

Jeuken, JWM ;

von Deimling, A ;

Wesseling, P .

JOURNAL OF NEURO-ONCOLOGY, 2004, 70 (02) :161-181

[44] Blockade of EGFR signaling promotes glioma stem-like cell invasiveness by abolishing ID3-mediated inhibition of p27KIP1 and MMP3 expression [J].

Jin, Xun ;

Jin, Xiong ;

Sohn, Young-Woo ;

Yin, Jinlong ;

Kim, Sung-Hak ;

Joshi, Kaushal ;

Nam, Do-Hyun ;

Nakano, Ichiro ;

Kim, Hyunggee .

CANCER LETTERS, 2013, 328 (02) :235-242

[45] Radiotherapy for glioblastoma in the elderly [J].

Keime-Guibert, Florence ;

Chinot, Olivier ;

Taillandier, Luc ;

Cartalat-Carel, Stephanie ;

Frenay, Marc ;

Kantor, Guy ;

Guillamo, Jean-Sebastien ;

Jadaud, Eric ;

Colin, Philippe ;

Bondiau, Pierre-Yves ;

Menei, Philippe ;

Loiseau, Hugues ;

Bernier, Valerie ;

Honnorat, Jerome ;

Barrie, Maryline ;

Mokhtari, Karima ;

Mazeron, Jean-Jacques ;

Bissery, Anne ;

Delattre, Jean-Yves ;

Lacomblez, L. ;

Levy-Soussan, M. ;

Mallet, A. ;

Houssard, C. ;

Delgadillo, D. ;

Poitou, M. ;

Hoang-Xuan, K. ;

Sanson, M. ;

Carpentier, A. F. ;

Laigle-Donadey, F. ;

Taillibert, S. ;

Cornu, P. ;

Omuro, A. ;

Capelle, L. ;

Boch, A. -L. ;

Duffau, H. ;

Simon, J. -M. ;

Medioni, J. ;

Broet, P. ;

Schmitt, A. ;

Garat, E. ;

Mathieu, P. ;

Camille, N. ;

Collin, J. -P. ;

Bailet, B. ;

Ciais, C. ;

Fauchon, F. ;

Lebrun, C. ;

Guesdan, G. ;

Stadelmaier, N. ;

Lombard, I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (15) :1527-1535

[46] Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951 [J].

Kouwenhoven, Mathilde C. M. ;

Gorlia, Thierry ;

Kros, Johan M. ;

Ibdaih, Ahmed ;

Brandes, Alba A. ;

Bromberg, Jacolien E. C. ;

Mokhtari, Karima ;

van Duinen, Sjoerd G. ;

Teepen, Johannes L. ;

Wesseling, Pieter ;

Vandenbos, Fanny ;

Grisold, Wolfgang ;

Sipos, Laszlo ;

Mirimanoff, Rene ;

Vecht, Charles J. ;

Allgeier, Anouk ;

Lacombe, Denis ;

van den Bent, Martin J. .

NEURO-ONCOLOGY, 2009, 11 (06) :737-746

[47] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma [J].

Kreisl, Teri N. ;

Kim, Lyndon ;

Moore, Kraig ;

Duic, Paul ;

Royce, Cheryl ;

Stroud, Irene ;

Garren, Nancy ;

Mackey, Megan ;

Butman, John A. ;

Camphausen, Kevin ;

Park, John ;

Albert, Paul S. ;

Fine, Howard A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :740-745

[48] Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance [J].

Kuhnt, Daniela ;

Becker, Andreas ;

Ganslandt, Oliver ;

Bauer, Miriam ;

Buchfelder, Michael ;

Nimsky, Christopher .

NEURO-ONCOLOGY, 2011, 13 (12) :1339-1348

[49] All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 [J].

Labussiere, M. ;

Idbaih, A. ;

Wang, X. -W. ;

Marie, Y. ;

Boisselier, B. ;

Falet, C. ;

Paris, S. ;

Laffaire, J. ;

Carpentier, C. ;

Criniere, E. ;

Ducray, F. ;

El Hallani, S. ;

Mokhtari, K. ;

Hoang-Xuan, K. ;

Delattre, J. -Y. ;

Sanson, M. .

NEUROLOGY, 2010, 74 (23) :1886-1890

[50] International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors [J].

Lassman, Andrew B. ;

Iwamoto, Fabio M. ;

Cloughesy, Timothy F. ;

Aldape, Kenneth D. ;

Rivera, Andreana L. ;

Eichler, April F. ;

Louis, David N. ;

Paleologos, Nina A. ;

Fisher, Barbara J. ;

Ashby, Lynn S. ;

Cairncross, J. Gregory ;

Roldan, Gloria B. ;

Wen, Patrick Y. ;

Ligon, Keith L. ;

Schiff, David ;

Robins, H. Ian ;

Rocque, Brandon G. ;

Chamberlain, Marc C. ;

Mason, Warren P. ;

Weaver, Susan A. ;

Green, Richard M. ;

Kamar, Francois G. ;

Abrey, Lauren E. ;

DeAngelis, Lisa M. ;

Jhanwar, Suresh C. ;

Rosenblum, Marc K. ;

Panageas, Katherine S. .

NEURO-ONCOLOGY, 2011, 13 (06) :649-659

← 1 2 3 4 5 6 7 8 9 10 →